دورية أكاديمية
أعرض في EDS

Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.

التفاصيل البيبلوغرافية
العنوان: Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
المؤلفون: Cheng TS; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK., Noor U; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK., Watts E; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA., Pollak M; Oncology Department, McGill University and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada., Wang Y; Oncology Department, McGill University and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada., McKay J; Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France., Atkins J; Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France., Masala G; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy., Sánchez MJ; Escuela Andaluza de Salud Pública (EASP), Granada, 18011, Spain.; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, 18012, Spain.; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, 28029, Spain.; Department of Preventive Medicine and Public Health, University of Granada, Granada, 18071, Spain., Agudo A; Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, L'Hospitalet de Llobregat, Barcelona, Spain.; Nutrition and Cancer Group; Epidemiology, Public Health, Cancer Prevention and Palliative Care Program; Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Castilla J; Instituto de Salud Pública de Navarra - IdiSNA, Pamplona, Spain.; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain., Aune D; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.; Department of Nutrition, Oslo New University College, Oslo, Norway.; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital Ullevå, Oslo, Norway., Colorado-Yohar SM; Department of Epidemiology, Murcia Regional Health Council-IMIB, Murcia, Spain.; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia., Manfredi L; Centre for Biostatistics, Epidemiology, and Public Health (C-BEPH), Department of Clinical and Biological Sciences, University of Turin, Orbassano, TO, Italy., Gunter MJ; Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC- WHO), Lyon, France., Pala V; Epidemiology and Prevention Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Josefsson A; Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Wallenberg Center for Molecular Medicin, Umeå University, Umeå, Sweden.; Department of Urology and Andrology, Institute of surgery and perioperative Sciences, Umeå University, Umeå, Sweden., Key TJ; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK., Smith-Byrne K; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK., Travis RC; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Oxford, OX3 7LF, UK. ruth.travis@ndph.ox.ac.uk.
المصدر: BMC cancer [BMC Cancer] 2024 Jun 03; Vol. 24 (1), pp. 676. Date of Electronic Publication: 2024 Jun 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2001-
مواضيع طبية MeSH: Prostatic Neoplasms*/blood , Prostatic Neoplasms*/epidemiology , Prostatic Neoplasms*/pathology , Insulin-Like Growth Factor I*/metabolism , Insulin-Like Growth Factor I*/analysis, Humans ; Male ; Middle Aged ; Case-Control Studies ; Prospective Studies ; Europe/epidemiology ; Aged ; Risk Factors ; Biomarkers, Tumor/blood ; Insulin-Like Peptides
مستخلص: Background: Circulating total insulin-like growth factor-I (IGF-I) is an established risk factor for prostate cancer. However, only a small proportion of circulating IGF-I is free or readily dissociable from IGF-binding proteins (its bioavailable form), and few studies have investigated the association of circulating free IGF-I with prostate cancer risk.
Methods: We analyzed data from 767 prostate cancer cases and 767 matched controls nested within the European Prospective Investigation into Cancer and Nutrition cohort, with an average of 14-years (interquartile range = 2.9) follow-up. Matching variables were study center, length of follow-up, age, and time of day and fasting duration at blood collection. Circulating free IGF-I concentration was measured in serum samples collected at recruitment visit (mean age 55 years old; standard deviation = 7.1) using an enzyme-linked immunosorbent assay (ELISA). Conditional logistic regressions were performed to examine the associations of free IGF-I with risk of prostate cancer overall and subdivided by time to diagnosis (≤ 14 and > 14 years), and tumor characteristics.
Results: Circulating free IGF-I concentrations (in fourths and as a continuous variable) were not associated with prostate cancer risk overall (odds ratio [OR] = 1.00 per 0.1 nmol/L increment, 95% CI: 0.99, 1.02) or by time to diagnosis, or with prostate cancer subtypes, including tumor stage and histological grade.
Conclusions: Estimated circulating free IGF-I was not associated with prostate cancer risk. Further research may consider other assay methods that estimate bioavailable IGF-I to provide more insight into the well-substantiated association between circulating total IGF-I and subsequent prostate cancer risk.
(© 2024. The Author(s).)
References: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):484-91. (PMID: 20142246)
World J Oncol. 2019 Apr;10(2):63-89. (PMID: 31068988)
Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. (PMID: 24840073)
J Clin Lab Anal. 1999;13(4):166-72. (PMID: 10414596)
Int J Cancer. 2022 Oct 1;151(7):1033-1046. (PMID: 35579976)
Prostate. 2022 Aug;82(11):1088-1097. (PMID: 35468227)
Int J Cancer. 2021 May 1;148(9):2274-2288. (PMID: 33252839)
Nat Rev Cancer. 2014 May;14(5):329-41. (PMID: 24722429)
Cancer Res. 2020 Sep 15;80(18):4014-4021. (PMID: 32709735)
Cancer Med. 2020 Sep;9(18):6836-6842. (PMID: 32717139)
Carcinogenesis. 2018 Dec 31;39(12):1431-1437. (PMID: 30165429)
J Clin Endocrinol Metab. 1999 Oct;84(10):3666-72. (PMID: 10523012)
Cancer Res. 2016 Apr 15;76(8):2288-2300. (PMID: 26921328)
J Cell Commun Signal. 2015 Jun;9(2):177-87. (PMID: 25617049)
J Clin Endocrinol Metab. 2004 Sep;89(9):4391-6. (PMID: 15356036)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi. (PMID: 22682634)
JNCI Cancer Spectr. 2021 Dec 15;6(1):. (PMID: 35047751)
Cancer Biol Ther. 2003 Nov-Dec;2(6):630-5. (PMID: 14688466)
Mol Metab. 2021 Oct;52:101245. (PMID: 33962049)
Public Health Nutr. 2002 Dec;5(6B):1113-24. (PMID: 12639222)
Maturitas. 1980 Jul;2(2):109-18. (PMID: 7193795)
Int J Cancer. 2019 Dec 15;145(12):3244-3256. (PMID: 30873591)
Int J Epidemiol. 2023 Feb 8;52(1):71-86. (PMID: 35726641)
Environ Int. 2021 Feb;147:106311. (PMID: 33348104)
Med Sci Sports Exerc. 2010 Jan;42(1):58-66. (PMID: 20010129)
Front Endocrinol (Lausanne). 2018 Apr 09;9:117. (PMID: 29686648)
فهرسة مساهمة: Keywords: Aggressiveness; Free IGF-1; Histological grade; Prostate cancer; Tumor stage
المشرفين على المادة: 67763-96-6 (Insulin-Like Growth Factor I)
0 (IGF1 protein, human)
0 (Biomarkers, Tumor)
0 (Insulin-Like Peptides)
تواريخ الأحداث: Date Created: 20240603 Date Completed: 20240604 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11145848
DOI: 10.1186/s12885-023-11425-w
PMID: 38831273
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا